---
title: The impact and future of obesity treatments like Ozempic
videoId: EixhVBV2yzo
---

From: [[acquiredfm]] <br/> 

## Introduction to GLP-1 Drugs and the Obesity Epidemic
Ozempic and Wegovy are sensational diabetes and weight-loss drugs developed by [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] <a class="yt-timestamp" data-t="00:00:37">[00:00:37]</a>. While the public perception is that these [[development_and_impact_of_glp1_drugs | GLP-1 drugs]] "magically appeared out of nowhere" <a class="yt-timestamp" data-t="00:03:04">[00:03:04]</a>, their development is rooted in decades of research <a class="yt-timestamp" data-t="00:02:56">[00:02:56]</a>.

The global prevalence of obesity and diabetes highlights the immense market for such treatments. Currently, 38 million Americans live with diabetes, and over 500 million people worldwide have the disease <a class="yt-timestamp" data-t="00:01:41">[00:01:41]</a>. Obesity affects approximately one billion people globally, including 40% of the U.S. population, expanding to 75% when considering overweight individuals <a class="yt-timestamp" data-t="00:01:56">[00:01:56]</a>. This massive market potential has made [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] Europe's largest company, surpassing LVMH <a class="yt-timestamp" data-t="00:01:14">[00:01:14]</a>.

### The Long Road to GLP-1 Success
The molecule semaglutide, found in Ozempic and Wegovy, was first trialed by [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] in 2008 for type 2 diabetes treatment, building on research from the early 1990s <a class="yt-timestamp" data-t="00:02:46">[00:02:46]</a>. The discovery that [[development_and_impact_of_glp1_drugs | GLP-1 drugs]] could reduce food intake was made in the mid-1990s, but clinical trials proving their effectiveness for weight loss were not completed until 2021 <a class="yt-timestamp" data-t="00:03:11">[00:03:11]</a>.

The company's singular focus on metabolic health, including insulin and diabetes, for over a century <a class="yt-timestamp" data-t="00:01:24">[00:01:24]</a>, played a crucial role in the eventual breakthrough of [[development_and_impact_of_glp1_drugs | GLP-1 drugs]].

#### The Pioneer: Lotte Bjerre Knudsen
A key figure in the development of [[development_and_impact_of_glp1_drugs | GLP-1 drugs]] at [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] is Lotte Bjerre Knudsen <a class="yt-timestamp" data-t="01:41:01">[01:41:01]</a>. Starting at Novo in 1989, she joined a team screening compounds for type 2 diabetes treatment in the early to mid-1990s <a class="yt-timestamp" data-t="01:45:00">[01:45:00]</a>. Academic research at the time suggested that the hormone glucagon-like peptide 1 (GLP-1) could stabilize insulin production in type 2 patients <a class="yt-timestamp" data-t="01:46:00">[01:46:00]</a>.

The major challenge was that natural GLP-1 is metabolized by the body in about five minutes <a class="yt-timestamp" data-t="01:46:51">[01:46:51]</a>. Despite industry abandonment of GLP-1 as a drug candidate due to this short half-life, Knudsen persisted <a class="yt-timestamp" data-t="01:47:19">[01:47:19]</a>. She developed an analog called liraglutide, which included a fatty acid to prevent rapid breakdown, extending its half-life to 13 hours <a class="yt-timestamp" data-t="01:48:49">[01:48:49]</a>. This made it a potential once-a-day drug <a class="yt-timestamp" data-t="01:50:28">[01:50:28]</a>.

#### The Gila Monster and Early Competitors
In a parallel development, American researchers in the VA hospital system discovered that a hormone in the venom of the Gila monster lizard also acted as a long-lasting [[development_and_impact_of_glp1_drugs | GLP-1 analog]] <a class="yt-timestamp" data-t="01:52:03">[01:52:03]</a>. This discovery led to the development of Byetta by Eli Lilly, the world's first [[development_and_impact_of_glp1_drugs | GLP-1 analog]] drug, approved for type 2 diabetes in 2005 <a class="yt-timestamp" data-t="01:51:10">[01:51:10]</a>. Byetta required two injections per day <a class="yt-timestamp" data-t="01:54:40">[01:54:40]</a>, making it less convenient than later drugs.

#### Overcoming Stigma: Weight Loss as a Medical Indication
Lotte Bjerre Knudsen and her R&D team pushed [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] to pursue FDA approval for liraglutide as a weight management drug <a class="yt-timestamp" data-t="02:00:05">[02:00:05]</a>. This was a challenging idea due to the immense stigma and dangerous history of weight loss drugs <a class="yt-timestamp" data-t="02:00:32">[02:00:32]</a>, such as Fen-Phen which caused major heart damage <a class="yt-timestamp" data-t="02:01:53">[02:01:53]</a>. As recently as 2005, [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]]'s CEO stated that "obesity is primarily a social and cultural problem" with "no business for [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] in that area" <a class="yt-timestamp" data-t="02:04:14">[02:04:14]</a>.

However, the safety profile of liraglutide, confirmed through extensive trials for diabetes, supported its potential for weight loss <a class="yt-timestamp" data-t="02:05:23">[02:05:23]</a>. In 2007, [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] began human trials for a higher-dose version of liraglutide for weight loss <a class="yt-timestamp" data-t="02:06:11">[02:06:11]</a>.

### The Rise of Victoza, Saxenda, Ozempic, and Wegovy
In 2010, Victoza (liraglutide for diabetes) received final approval and became a "Blockbuster" drug, achieving over a billion dollars in sales in its first full year <a class="yt-timestamp" data-t="02:08:05">[02:08:05]</a>. Much of this success was driven by off-label use for weight loss <a class="yt-timestamp" data-t="02:09:40">[02:09:40]</a>.

Saxenda, the official weight-loss version of liraglutide, was submitted for approval in late 2013 <a class="yt-timestamp" data-t="02:11:16">[02:11:16]</a>. While a hit, it only yielded an average of 8% BMI reduction, just below the perceived "magical 10% weight loss reduction number" needed for widespread adoption <a class="yt-timestamp" data-t="02:12:01">[02:12:01]</a>.

The game-changer was semaglutide. In 2016, [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] began Phase 3 trials for semaglutide, a next-generation [[development_and_impact_of_glp_1_drugs | GLP-1 analog]] <a class="yt-timestamp" data-t="02:14:51">[02:14:51]</a>. Semaglutide had two key advantages over liraglutide:
1.  **Once-weekly injection**: Much longer lasting in the body, a significant convenience benefit <a class="yt-timestamp" data-t="02:15:39">[02:15:39]</a>.
2.  **Increased efficacy**: Twice as effective for weight loss, yielding 15% or more long-term BMI reduction, surpassing the 10% threshold <a class="yt-timestamp" data-t="02:15:54">[02:15:54]</a>.

Ozempic (semaglutide for diabetes) launched in 2018 and quickly became a huge hit, generating over a billion dollars in revenue in its first year despite supply constraints <a class="yt-timestamp" data-t="02:19:24">[02:19:24]</a>. When Wegovy (semaglutide for weight loss) launched in the U.S. in 2021, it received as many prescriptions in its first month as Saxenda had in its entire lifetime <a class="yt-timestamp" data-t="02:21:07">[02:21:07]</a>. The New York Times called it a "game-changer" <a class="yt-timestamp" data-t="02:21:42">[02:21:42]</a>.

As of early 2024, [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]]'s market cap has soared to nearly half a trillion dollars <a class="yt-timestamp" data-t="02:22:44">[02:22:44]</a>. [[development_and_impact_of_glp_1_drugs | GLP-1 drugs]] now account for 69% of their revenue <a class="yt-timestamp" data-t="02:23:20">[02:23:20]</a>, with insulin comprising 22% <a class="yt-timestamp" data-t="02:23:46">[02:23:46]</a>.

### How GLP-1 Drugs Work for Weight Loss
[[development_and_impact_of_glp_1_drugs | GLP-1 drugs]] like semaglutide primarily work through two mechanisms:
1.  **Satiety Signals**: The natural GLP-1 hormone travels to the brain, triggering a response that signals fullness and reduces hunger <a class="yt-timestamp" data-t="02:16:49">[02:16:49]</a>. This can quiet the impulse to fixate on food <a class="yt-timestamp" data-t="02:17:02">[02:17:02]</a>.
2.  **Slowed Digestion**: The drugs also slow down how quickly food moves through the digestive system, prolonging the feeling of fullness <a class="yt-timestamp" data-t="02:17:18">[02:17:18]</a>.

While semaglutide doesn't override the laws of thermodynamics (calorie intake vs. expenditure) <a class="yt-timestamp" data-t="02:18:26">[02:18:26]</a>, it naturally changes habits by reducing the desire to eat large quantities or calorie-dense foods <a class="yt-timestamp" data-t="02:18:41">[02:18:41]</a>. Common side effects include nausea, vomiting, and constipation <a class="yt-timestamp" data-t="02:17:41">[02:17:41]</a>, with about one in six patients discontinuing due to severe side effects <a class="yt-timestamp" data-t="02:17:54">[02:17:54]</a>.

## Economic and Societal Implications

### Pricing and Access in the U.S.
In the U.S., the sticker price for Ozempic (diabetes) is over $1,000 per month, and for Wegovy (weight loss) it's over $1,300 per month <a class="yt-timestamp" data-t="02:27:30">[02:27:30]</a>. This contrasts sharply with prices in Canada ($147/month for Ozempic) and the UK ($93/month) <a class="yt-timestamp" data-t="02:27:47">[02:27:47]</a>, making high costs a "uniquely American problem" <a class="yt-timestamp" data-t="02:27:55">[02:27:55]</a>.

Insurance coverage is complex:
*   **Private Insurers**: Often have a mismatch in time horizons. They are incentivized to cover conditions that pay back within the average 3.7-year employee tenure <a class="yt-timestamp" data-t="02:28:34">[02:28:34]</a>. Long-term benefits like preventing future complications from obesity don't align with their short-term incentives <a class="yt-timestamp" data-t="02:29:20">[02:29:20]</a>.
*   **Medicare (U.S. Government)**: Medicare Part D, which covers prescription drugs, is legally prohibited from paying for weight loss medications <a class="yt-timestamp" data-t="02:30:53">[02:30:53]</a>. This prohibition is partly due to the historical stigma of obesity as a lifestyle problem rather than a disease <a class="yt-timestamp" data-t="02:31:12">[02:31:12]</a>, despite scientific evidence to the contrary <a class="yt-timestamp" data-t="02:31:32">[02:31:32]</a>. However, since most Americans eventually go on Medicare, the government ultimately bears the long-term healthcare costs of obesity-related comorbidities <a class="yt-timestamp" data-t="02:32:04">[02:32:04]</a>.

Even with insurance, many patients pay around $300/month <a class="yt-timestamp" data-t="02:38:02">[02:38:02]</a>, creating an access problem alongside the supply constraint <a class="yt-timestamp" data-t="02:38:51">[02:38:51]</a>. Non-adherence is also a significant issue, with up to 68% of people rolling off the drug after a year, leading to weight regain <a class="yt-timestamp" data-t="02:39:10">[02:39:10]</a>.

### Industry Landscape and Future Outlook

#### Eli Lilly's Emergence
Other major pharmaceutical companies are also developing [[development_and_impact_of_glp_1_drugs | GLP-1 drugs]]. Eli Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) is a dual [[development_and_impact_of_glp_1_drugs | GLP-1]]/GIP receptor agonist, showing promising results that may be even more effective for weight loss and insulin production than semaglutide <a class="yt-timestamp" data-t="02:35:09">[02:35:09]</a>. Zepbound received official FDA approval for weight loss in November 2023 <a class="yt-timestamp" data-t="02:35:50">[02:35:50]</a>.

#### Pipeline and Potential New Indications
The intense demand ensures there is "room for everybody" <a class="yt-timestamp" data-t="02:35:50">[02:35:50]</a>. [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] has its own next-generation [[development_and_impact_of_glp_1_drugs | GLP-1 drugs]] in the pipeline, such as CagriSema, and an oral version of semaglutide (Rybelsus) <a class="yt-timestamp" data-t="02:36:35">[02:36:35]</a>.

Beyond weight loss, the long half-life of semaglutide allows it to reach other tissues in the body, suggesting potential benefits for other organs. [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] is currently conducting clinical trials for semaglutide in treating cardiovascular disease, Alzheimer's, and kidney disease <a class="yt-timestamp" data-t="02:26:19">[02:26:19]</a>. If these prove successful, it could earn the title of "miracle drug" for humanity <a class="yt-timestamp" data-t="02:26:57">[02:26:57]</a>.

The [[development_and_impact_of_glp_1_drugs | GLP-1]] super cycle is expected to involve "ever stacking waves of patentable innovation and product innovation" <a class="yt-timestamp" data-t="02:46:49">[02:46:49]</a>, similar to the evolution of insulin treatments over the last century <a class="yt-timestamp" data-t="02:46:58">[02:46:58]</a>.

### Risks and Considerations
While the outlook is largely positive, potential downsides include:
*   **Muscle Mass Loss**: Early studies suggest that patients on [[development_and_impact_of_glp_1_drugs | GLP-1 drugs]] may lose a disproportionate amount of lean muscle mass compared to traditional diet and exercise (around 40% vs. 25% of weight loss) <a class="yt-timestamp" data-t="03:35:50">[03:35:50]</a>.
*   **Suicidal Thoughts**: There have been anecdotal discussions about suicidal thoughts, but current research and regulatory bodies do not indicate this is a major risk based on broad population studies <a class="yt-timestamp" data-t="03:36:34">[03:36:34]</a>.

## Playbook: Concentration and Long-Term Focus
[[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]]'s success is a testament to extreme concentration and long-term focus <a class="yt-timestamp" data-t="02:56:43">[02:56:43]</a>. The company has maintained a narrow focus on metabolic disorders for over a century, despite being urged to diversify <a class="yt-timestamp" data-t="02:56:50">[02:56:50]</a>. This dedication allowed them to build deep expertise and iterate over decades, eventually leading to the [[development_and_impact_of_glp_1_drugs | GLP-1]] breakthrough.

The unusual governance structure, where a non-profit foundation owns and controls the company <a class="yt-timestamp" data-t="01:32:00">[01:32:00]</a>, also contributed to this long-term view. The foundation's objectives prioritize "stability and supporting scientific and humanitarian causes" over immediate growth, aligning incentives for long-term R&D <a class="yt-timestamp" data-t="03:01:28">[03:01:28]</a>. This contrasts with other pharmaceutical companies that historically shifted to "specialty drugs" for smaller, highly profitable markets <a class="yt-timestamp" data-t="03:07:32">[03:07:32]</a>, fearing the high costs and low success rates of mass-market drug development <a class="yt-timestamp" data-t="03:10:55">[03:10:55]</a>.

> "There is a reasonable Narrative of it's their long time Horizon and their focus their ability to learn from doing the same thing well and iterating of over a hundred years that actually LED them to find this breakthrough when others didn't" <a class="yt-timestamp" data-t="03:06:22">[03:06:22]</a>

## Value Creation and Capture
There is "undeniable" value creation by [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] through its history, especially for diabetics and now a much broader population <a class="yt-timestamp" data-t="03:22:55">[03:22:55]</a>. As a half-trillion-dollar company with high profitability (84% gross margins, 10 percentage points higher than average big Pharma) <a class="yt-timestamp" data-t="02:24:28">[02:24:28]</a>, it has also captured significant value.

The pharmaceutical industry overall is a high-risk, high-return venture business, with only 10% of drugs that enter clinical development making it to market, and one drug often providing half of a company's profits <a class="yt-timestamp" data-t="03:12:32">[03:12:32]</a>. While the sticker prices of [[development_and_impact_of_glp_1_drugs | GLP-1 drugs]] are high, pharmaceutical companies argue that high margins are necessary to cover the tremendous R&D investment, including the many drug failures <a class="yt-timestamp" data-t="03:24:04">[03:24:04]</a>.

> "The improved ability to move a drug from place a to place B and come up with yet another clever way to build out the formulary so it moves money from this pocket to that pocket hospitals if you back out the drugs they prescribe hospitals are 28% of the revenue in all of healthcare which is large but hospitals provide a crap ton of value Professional Services like doctor's offices are 26% they also provide a lot of value do both of them provide together four times as much value as the Breakthrough drugs do I mean freaking health insurance the administrative costs of health insurance are 8% of a very very very large number" <a class="yt-timestamp" data-t="03:28:02">[03:28:02]</a>

While pharmaceutical companies take significant innovation risks, other parts of the U.S. healthcare system, like insurance companies and Pharmacy Benefit Managers (PBMs), are often criticized for high administrative costs and consolidation without commensurate risk-taking or innovation <a class="yt-timestamp" data-t="03:29:29">[03:29:29]</a>.

## Bull and Bear Case

### Bull Case
The core bull case for [[novo_nordisks_insulin_and_diabetes_history | Novo Nordisk]] and [[development_and_impact_of_glp_1_drugs | GLP-1 drugs]] is whether they represent "the next Super Cycle" in pharmaceuticals <a class="yt-timestamp" data-t="03:18:18">[03:18:18]</a>. If so, there is ample room for multiple competitors like Eli Lilly, given the massive demand and high barriers to entry <a class="yt-timestamp" data-t="03:33:32">[03:33:32]</a>. Further innovations and iterations, like triple agonists such as Eli Lilly's retatrutide, could continue to drive market growth <a class="yt-timestamp" data-t="03:35:14">[03:35:14]</a>.

### Bear Case
The bear case hinges on whether [[development_and_impact_of_glp_1_drugs | GLP-1 drugs]] will "not play out" <a class="yt-timestamp" data-t="03:34:04">[03:34:04]</a> in the long term, either due to unforeseen health risks, lack of sustained efficacy, or other factors not yet fully understood <a class="yt-timestamp" data-t="03:34:04">[03:34:04]</a>.